Prezentare companie · for a bright future We adapt our human resources at the strategic directions...
Transcript of Prezentare companie · for a bright future We adapt our human resources at the strategic directions...
Prezentare companie
A brief history of Antibiotice
www.antibiotice.ro
2000-2010 1990-1999 1955-1990
1955
The first company
manufacturing Penicillin
in Romania and
Southeast Europe,
bearing the name of
Chemical Factory no. 2
was set up.
Our company enlarged its
manufacturing structure with
various active substances,
sterile powders for injection,
ointments and suppositories.
Our company massively invested
to modernize the technologies and
certify the quality systems for
meeting the GMP and US FDA
standards;
The manufacturing flows of
Nystatin and sterile powders for
injection were FDA certified;
Antibiotice launched its new
brand identity.
Manufacturing structure
was continuously
redefined;
As of 1997 Antibiotice has
been listed on the
Bucharest Stock Exchange.
BVB symbol: ATB
a+
A brief history of Antibiotice
www.antibiotice.ro
2015
Our company opened its own Center for
Drug Evaluation;
It has become the first European WHO pre-
qualified company for anti-tuberculosis
medicines;
Our Nystatin is a USP reference standard.
Present
Antibiotice has become a world leader in the
production of Nystatin;
Our product portofolio comprises more than
150 medicinal products from 11 therapeutic
classes.
2010
BVB symbol: ATB
MISSION
We make our valuable medicines more accessible to patients, physicians and pharmacists. We
always put our strength to the service of those who need our support.
VISION
The Hippocratic spirit that guides the practice of medicine and pharmacy also guides our actions.
We are honest, compassionate and constantly concerned with modernizing our activity and
enhancing our products. We believe a valuable medicine is not necessarily an expensive one but
a medicine people can afford and which brings the company a reasonable profit. Profit that
satisfies our shareholders and allows us to target performance, permanently investing in people,
technology and carefully selected partnerships.
We cherish efficiency, knowledge and spirit of cooperation which allow us to focus on the ever-
changing needs of our customers and consumers.
In our company, we put the right people in the right place at the right time. We mutually
acknowledge our purpose and value, which creates a sense of connection and gives us the strength
to overcome limitations and obstacles.
As human beings, we care about our fellows, we seek to be close to them and we always think about
how to improve things that are important to them.
VALUES
07 JUNE 2017 Mission, Vision, Values
BVB symbol: ATB
www.antibiotice.ro
Shareholding and evolution of shares
BVB symbol: ATB
www.antibiotice.ro
S.I.F. Oltenia
18.8999 %
28.0829%
Ministry of Health Other
shareholders 53.02 %
Bucharest Stock Exchange ATB
Number of shares 671,338,040
Nominal value of shares 0.1000 LEI
Market capitalization – 30.09.2019 342,382 thousand LEI
640.821 690.663 319.854 438.299
361.445
23.662.333
501.452
703.793 444.776
134 151
157
182 161 164 168
213
175
0
100
200
300
400
500
0
2.000.000
4.000.000
6.000.000
8.000.000
10.000.000
12.000.000
14.000.000
16.000.000
18.000.000
20.000.000
22.000.000
24.000.000
Nr.
tra
nzacţi
i
Nr.
acţi
un
i
Evolution of number of traded shares and number of transactions in 2019
Nr. actiuni
Nr. Tranzactii
22 years in the capital market
BVB symbol : ATB
27.8 million of shares, with a total value
of 2.9 million EUR, were traded in the first
9 months of 2019..
2.9 million EUR
More than 734 million of shares, with a
total trading value of 118 million EUR
were traded.
118 million EUR
Antibiotice, listed in the Premium
category of the Bucharest Stock
Exchange
April 1997
ATB shares have been included in the
ROTX index of the Vienna Stock
Exchange
2005 2007
ATB shares have been included in the Dow
Jones Wilshire Global Total Market index of
the New York Stock Exchange and in the
BET index (Bucharest Exchange Trading)
www.antibiotice.ro
Strategic development pillars
We
strategically
adjust our
product
portfolio
Investments
-
the guarantee
for a bright
future
We adapt our
human
resources at the
strategic
directions
Integrated
quality
management
Our business expands
internationally and
strengthens
internally
BVB symbol: ATB
www.antibiotice.ro
Our business expands internationally
10%
Russia
& CIS 19%
Europe
5% South
America
23% North
America
2%
Africa
EXPORT 42 % din total vânzări
40%
Asia
1%
Australia
Our own representative
offices in the Republic
of Moldova, Ukraine and
Serbia
36 million USD in 2019 (E)
50 internationally registered
products
Ongoing international projects
worth 14.3 million USD in the
U.S., EU and Southeast Asia
Vietnam
World leading manufacturer of
Nystatin API
BVB symbol : ATB
www.antibiotice.ro
Strategies for internationalizing our business
To strengthen our leading position in the Nystatin market
To expand our presence in North America and in the territories with Antibiotice representative offices
To access new markets with a high consumption potential for our core portfolio
A DOUBLED TURNOVER UNTIL 2025
BVB symbol: ATB
www.antibiotice.ro
Antibiotice today
www.antibiotice.ro
Active substance
Market share
Market share
Market share 1
GENERICS
1 WORLDWIDE
1 INJECTABLES
1 TOPICALS
The most important Romanian manufacturer of
generic medicines
Leader in the production of injectable beta-lactam
antibiotics in Romania
Leader in the segment of topical products
(creams, ointments, gels)
10%
84%
24%
World leader in the production of Nystatin -
active substance 65%
BVB symbol: ATB
Antibiotice today
www.antibiotice.ro
70 COUNTRIES
11 THERAPUTIC
AREAS
An internationally present company
A portfolio comprising more than 150 products from
the following therapeutic areas – antiinfectives,
cardiovasculars, dermatologicals, digestive tract
system, central nervous system, genitourinary system;
35%
150
It invests 5% of turnover in
research – development projects 5
R&D
5%
BVB symbol: ATB
Legislation
We provide
Distributors
Clients
NAMMDR – issues the Marketing
Autorizations - Law no. 95/2006 updated
RX pricing regulation – Order no.
368/2017 updated
- RX – Prescription medicines
- OTC – Non-prescription medicines
- Food supplements and dermatocosmetics
Alliance Healthcare România SRL, Dona Logistică SRL,
Europharm Holding SRL, Farmaceutica Remedia
Distribution&Logistics SRL, Farmexim SA, Fildas Trading,
Mediplus Exim SRL, Pharma SA, Pharmafarm SA, Romastru
Trading SRL
520 hospitals
8,000 pharmacies
National pharmaceutical market
BVB symbol: ATB
www.antibiotice.ro
Romanian pharmaceutical market
Romanian market 17.5 billion LEI 100%
Relevant market 2.07 billion LEI 12%
Antibiotice market 340.04 million LEI 2%
RETAIL
88%
HOSPITAL
12%
*Data source: Cegedim Romania
July 2018 - June 2019
BVB symbol: ATB
www.antibiotice.ro
23% 77%
Romanian market Antibiotice market
78%
22%
VALUE
65%
35%
QUANTITY
RX OTC
Partner of the Ministry of Health on the TB
program, with a 90.5% market share of total
consumption.
Leader in the ointment segment in terms of units
sold (23.9% market share in indivisible units).
Leader in the suppository segment in terms of
units sold (42.4% market share in indivisible units).
Leader in the injectable powder segment in terms
of units sold (72.2% market share in indivisible
units). 60%
40%
VALUE
25%
75%
QUANTITY
INOVATOR GENERICE * Data source:
Cegedim Romania
June 2019
Antibiotice in the national market
BVB symbol: ATB
www.antibiotice.ro
Consolidated portfolio in prospective therapeutic areas
BVB symbol: ATB www.antibiotice.ro
Hospital & Partners
Women's health
Semisolid and solid topicals (ointments, creams, gels, pessaries and suppositories
Life quality
Cardiovasculars
Nutriensa®
Hospital portfolio
.
.
Well-known manufacturer of injectable and oral anti-infectives
It covers up all the subclasses of antibiotics
Investments for expanding the hospital portfolio in the international market
penicillins, cephalosporins, carbapenems, polymyxins.
In Vietnam
Our company has been supporting the health programs for prophylaxis and treatment of infectious diseases.
We aim at increasing our business in this market up to 10 million USD
Beta-lactam antibiotics in combination with beta-lactamase inhibitors manufactured by Antibiotice in all hospitals in Vietnam.
In Ukraine
Registration of our hospital portofolio - 2019
Our first medicinal products in the hospital market - QI 2021
Estimated increase in turnover up to 3 million USD in 2025.
Exploring the potential of using a number of sterile medicines (anti-infectives, cardiovasculars, for digestive tract and CNS) in hospitals,
partnerships for investments in research and production of sterile medicines for hospitals in the period 2025-2030.
BVB symbol: ATB www.antibiotice.ro
Hospital & Partners
.
04A new manufacturing plant for topicals – a doubled production capacity;
The range of 38 molecules (ointments, creams, gels and suppositories), recommendations in the medical guidelines for
psoriasis, osteoarthritis / osteoarthrosis, skin and gynecological infections and other dermatological disorders;
Development perspectives through internationalization.
Cardiovascular diseases are the main cause of morbidity and mortality in Romania, with 57% of all deaths nationally recorded;
A continuous development of the medicines from all the therapeutic subclasses recommended by international guidelines and
protocols as first intention medicines;
Antibiotice will develop its portfolio which currently comprises 10 molecules with various therapeutic concentrations to
become a complete alternative for healthcare professionals and an accessible option for patients.
Nutriensa® – food supplements for the cardiovascular system, central nervous system, osteoarticular system and digestive
tract.
BVB symbol : ATB www.antibiotice.ro
Semisolid and solid topicals (ointments, creams, gels, pessaries and suppositories
Life quality
The growth expected in the years to come from these pharmaceutical forms through internationalizing the dermatology and
women‘s health portofolios;
Research & Development
www.antibiotice.ro
.
Research -
Development
10 million EUR investment
100 SPECIALISTS
Fields of activity:
Pharmaceutical development &
analytical research
Technological transfer
Portfolio management
Regulatory Affairs
Intellectual property
CENTER FOR CLINICAL STUDIES
Our accumulated knowledge and
experience allow us to develop future
projects oriented towards the health of
patients;
One of the most modern centers for
clinical studies in Romania;
Established in 2005, through 1 million
EUR investment in technology and
equipment;
Bioequivalence studies, phase I clinical
studies;
Therapeutic efficacy studies in
partnership with university centers.
BVB symbol: ATB
13-15 new projects/year
Pharmacovigilance system connected to Eudravigilence
The key component of our development approach
Multidisciplinary R&D team
BVB symbol: ATB www.antibiotice.ro
3 29
1
1
10 Our specialists are licensed in fields
such as :
Pharmacists
Chemists
Biochemists
Chemical
engineers Physicists
Bioengineers
Physicians
Biologists
More than 35% of our R&D
specialists have a PhD.
21 5
32
8 GMP and FDA authorized manufacturing flows - a portfolio of
generics from 11 therapeutic areas
Production adjusted to the market’s demands
BVB symbol: ATB
Cardiovasculars
Digestive tract and metabolism
Musculoskeletal system
Genito-urinary system
Anti-infectives for systemic use
Central nervous system
Dermatologicals
Food supplements
www.antibiotice.ro
Investments – the guarantee for a bright future
Investments in
research
The medium- and long-term development is
based on:
Upgrading the
existent
manufacturing
facilities
Investments in new
facilities
Investments in
product quality
control,
environmental
protection,
occupational health
and safety
Investments in IT
infrastructure and for
modernizing the
interior and exterior
of the company
15% of total income assigned for investments
BVB symbol: ATB www.antibiotice.ro
BVB symbol: ATB
www.antibiotice.ro
10 million EUR
20 million EUR
60 million EUR
A new manufacturing plant
for ointments & suppositories
Upgrading and expanding the
Biosynthesis Plant in which the
active substance Nystatin is
manufactured and in diversifying
the product range
Manufacturing plant for sterile
injectable solutions
We keep investing in
Strategic objectives of the human resource policy
BVB symbol: ATB www.antibiotice.ro
Partner of the
university
system
The most important
employer with a
majority Romanian
capital in the
North-East region
HR
To support the professional performance and career development
To create a balanced staff structure
To increase our employees' motivation
To improve the organizational climate Specialists with
experience in
research, quality
assurance,
production, marketing
etc.
Diversity and high professional qualification
7.80 %
Doctors and
Pharmacists
15.80 %
Biologists
1,420
employees In the last decade, considering the increased complexity of our activity, there is an upward
trend regarding the percentage of people with higher education.
.
We owe our success to our highly qualified specialists, dedicated to the company’s mission and brand values
3.2 % 29.10 % Chemists, Physicists,
Chemical Engineers
11.60 %
Engineers of different
specializations
23 %
Economists IT specialists
10 %
Other areas
Secondary education employees (56%) Higher education employees (44%)
BVB symbol: ATB
www.antibiotice.ro
Attractive brand for our future employees
*
Partnerships with the University of Medicine and
Pharmacy (UMF) Iasi
300 graduate students
46 graduates employed in R&D
10 editions
Students with various specializations (biologists,
chemists, chemical engineers, pharmacists)
Over 50 participants; 12 of them already
employed
4 editions
Projects in perspective
Academia+
Dual education
Projects in progress
Request for a class in 2019 for 2020-2023
Practice provided for 2-3 generations
Creating real perspectives for setting up the
Antibiotice Dual Education School.
Initiatives aimed at ensuring the training of the skills needed to reach the objectives
and increase the degree of involvement
In-depth specialization in the pharmaceutical
industry for graduates with higher education through
fundraising
Long-term training internships (6 months).
BVB symbol: ATB
www.antibiotice.ro
Integrated quality management system
BVB symbol: ATB
www.antibiotice.ro
US - FDA for sterile injectable powders
and the active substance Nystatin
CoS (Certificate of Suitability) for
micronized Nystatin issued by EDQM
WHO – pre-qualification for anti-TB drugs
Integrated quality management system
(quality, environment, occupational health and security)
Our active substance Nystatin – international
standard
EU-GMP for 8 manufacturing flows
We design a high-performing future
BVB symbol: ATB
www.antibiotice.ro
243,6
331 365
403
0
50
100
150
200
250
300
350
400
450
2010 2015 2018 2019(E)
Turnover million LEI
57,1
92,7
124
140
0
20
40
60
80
100
120
140
160
2010 2015 2018 2019(E)
Export million LEI
18
32
35 35
0
5
10
15
20
25
30
35
40
2010 2015 2018 2019(E)
Profit Million LEI
We produce medicines with science and we put our soul in what we do. We take the responsibility to contribute as a "good
citizen" to the life of our community, directly involving ourselves in developing a better society and a cleaner environment.
People, community and environment - our main responsibilities
BVB symbol: ATB
www.antibiotice.ro
HEALTH
EDUCATION
SOCIAL PERFORM a+
ENVIRONMENT
Antibiotics of the 3rd
Millennium
Donate blood! Put your soul
to life!
Power of Deed
Be generous, be Santa
Claus!
We invest in a high-
performing future -
Perform a+ and Summer
School a+
Science and Soul
Scholarships
We invest in excellence –
We support the national
and international Olympic
students
Be Pro-Nature! Put soul!
The Orchard at School
BVB symbol: ATB
www.antibiotice.ro
Contact: Investor Relations
Tel: 0232 – 209 583
Email: [email protected]
Thank you!
Financial indicators
www.antibiotice.ro Simbol BVB: ATB
No. Indicators UM 2016 2017 2018 06/30/2019
1 Sales income Mil Lei 332 336.9 365 172
1,1 Internal Mil Lei 227.4 219.4 241 100
1,2 Export Mil Lei 105 117.5 124 72
1,3 Export weight in turnover % 32% 35% 34% 42%
2 Gross profit Mil Lei 35 35 35 25
3 Equity Mil Lei 409 417 473 488
4 Total debts Mil Lei 124 154 231 247
5 Total active Mil Lei 533 573 706 742
6 Debt Degree (Total Debt / Total Assets) % 23% 27% 33% 33%
7 Liquidity (Total Assets / Total Liabilities) 4.3 3.7 3.1 3.0
8 Total expenses per 1000 lei revenue 899 899 907 879
9 Work productivity (Revenue / Persons Exploited) K Lei
/Employee 234 243 261 144
10 Taxes and taxes, of which: Mil Lei 79 76 89 45
10,1 - claw back rate Mil Lei 22 29 36 20
11 Added value Mil Lei 167 170 188 103
12 Gross profitability (Gross profit / Sales revenue) % 10% 10% 10% 14%
Disclaimer
This presentation does not constitute and should not be construed as representing or being part of any current offer to sell or issue shares, or as a purchase or
subscription request for any shares issued by Antibiotice S.A.
No part of this presentation may be invoked in connection with any investment contract or decision nor does it constitute a recommendation regarding securities
issued by Antibiotice S.A.
These statements reflect the current knowledge of the company as well as the forecasts for future events, having an anticipatory character. By their nature,
anticipatory statements are subject to a number of risks and uncertainties, many of which are beyond the control of Antibiotice SA which could determine the actual
results and performance of the company to differ significantly from the results and performance expressed or suggested by the anticipatory statements.
None of the forecasts, expectations, estimates or prospects in this presentation should be considered as certainties or promises, nor should they be considered as
implying an indication, assurance or guarantee that the assumptions based on which the future forecasts, expectations, estimates or perspectives were elaborated
are complete.
This presentation is not intended to contain all the information that may be required regarding Antibiotice SA or its shares and each person receiving this
presentation must make an independent assessment.
The trading company undertakes no obligation to publicly release the results of any revisions to these anticipatory statements contained in this presentation that
may arise as a result of changes in its forecasts or to reflect events or circumstances occurring after the date of this document.
This presentation and its content are the Antibiotice S.A. property and no part of this document may be reproduced or redistributed to another person.
Simbol BVB: ATB www.antibiotice.ro